Comparison · NCT05842941-deaths
DNL343 vs Matching Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. DNL343 vs Matching Placebo: deaths from any cause. Trial comparisons, record NCT05842941-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05842941-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0323 | 0.0149 | 0.0686 | wilson | |
| Risk in group 2 | 0.0476 | 0.0163 | 0.131 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0154 | -0.1 | 0.0326 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.677 | 0.175 | 2.63 | log | |
| Odds ratio, group 1 over group 2 | 0.667 | 0.162 | 2.75 | log | |
| Number needed to treat, for one fewer death from any cause on DNL343 than on Matching Placebo | 65.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | DNL343 | DNL343 is administered orally once a day for 24 weeks. | 6 | 186 | EG000 |
| Group 2 | Matching Placebo | Matching Placebo is administered orally once a day for 24 weeks. | 3 | 63 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Up to 35 weeks after participant signed Master Protocol consent. For safety analyses, the analysis populations include all anticipated and unanticipated safety events (i.e. Deaths, Serious Adverse Events, and Other Adverse Events) due to any cause, that occurred or worsened on or after treatment initiation to either the final safety visit, the date of death, the date of last study contact, or the date of first dose of study drug during participation in the ATE period.
Source ClinicalTrials.gov
Trial
- Title
- HEALEY ALS Platform Trial - Regimen G DNL343
- NCT number
- NCT05842941
- Phases
- PHASE2, PHASE3
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- DNL343, Matching Placebo
- Lead sponsor
- Merit E. Cudkowicz, MD
- Results first posted
- 2026-01-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05842941?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05842941-deaths